Skip to content

A clinical trial to study the effects of alternate day fasting and the 5:2 diet on adults with overweight and obesity.

Comparison of the effectiveness of different regimens of intermittent fasting in overweight and obese adults. - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070656
Enrollment
120
Registered
2024-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E66- Overweight and obesity

Interventions

Intervention1: Alternate Day Fasting (ADF): Participants to fast on alternate days, consuming only 25% of one day calorie requirement. A routine diet on non-fasting days. Intervention2: The 5:2 Diet:

Sponsors

Maulana Azad Medical College and Associated Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Body Mass Index equals or greater than 23 kilograms per square meter (as per WHO Asian BMI classification), 2. Able to give informed consent, 3. Not planning to relocate within 6 months of the study, 4. Willing to participate in this weight loss intervention.

Exclusion criteria

Exclusion criteria: 1. Individuals suffering from disorders like Celiac disease, uncontrolled thyroid disorder, anorexia bulimia. 2. Individuals with comorbid conditions in which dietary restrictions will be detrimental like individuals with Stroke, Cardiomyopathy, Coronary artery disease, other Cardio-vascular disease, Chronic Obstructive Pulmonary Disease, Alzheimers disease, Depression. 3. Individuals who have previous weight loss surgery, moderate or severe chronic hepatorenal diseases or cardio-cerebrovascular diseases, current acute complications of diabetes, such as diabetic ketosis, hyperglycaemia and hypertonicity in the past 3 months, stress diseases such as surgery, trauma, and cardiovascular and cerebrovascular events, and mental disorders requiring antipsychotic drugs. 4. Women who are lactating, pregnant or planning for pregnancy. 5. Individuals undergoing some weight loss intervention or have undergone weight loss intervention within 3 months tim

Design outcomes

Primary

MeasureTime frame
Change in body weight, body mass indexTimepoint: At Baseline 0 week At Midline 6 weeks At Endline 12 weeks

Secondary

MeasureTime frame
Lipid levels, Fasting Blood Glucose, HbA1C, HOMA IR, Fasting insulin, Ferritin, IL-6, Adiponectin, Total energy intake. Improvement in quality of life and parameters like physical, emotional and social well-beingTimepoint: At Baseline 0 week At Endline 12 weeks;reduction in body fat, visceral fat, improvement in waist to hip ratioTimepoint: At Baseline 0 week At Midline 6 weeks At Endline 12weeks

Countries

India

Contacts

Public ContactShikha Goel

Maulana Azad Medical College and Associated Hospitals

drsandeepgargmamc@gmail.com01123239271

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026